Leerink Partnrs Has Negative Outlook for BMY Q3 Earnings

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Leerink Partnrs reduced their Q3 2025 earnings per share estimates for shares of Bristol Myers Squibb in a note issued to investors on Wednesday, July 9th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will earn $1.67 per share for the quarter, down from their prior estimate of $1.69. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol Myers Squibb's Q4 2025 earnings at $1.65 EPS, FY2028 earnings at $5.57 EPS and FY2029 earnings at $6.07 EPS.

Several other research firms have also commented on BMY. Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. UBS Group dropped their target price on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Jefferies Financial Group decreased their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Piper Sandler began coverage on Bristol Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target on the stock. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $57.69.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock traded up $0.88 during trading hours on Thursday, reaching $48.54. The company's stock had a trading volume of 14,726,489 shares, compared to its average volume of 12,862,426. Bristol Myers Squibb has a one year low of $39.93 and a one year high of $63.33. The stock has a market cap of $98.78 billion, a P/E ratio of 18.18, a price-to-earnings-growth ratio of 1.41 and a beta of 0.36. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The company's 50 day simple moving average is $47.60 and its 200 day simple moving average is $53.42.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. Bristol Myers Squibb's quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the firm earned ($4.40) EPS.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.11%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is presently 92.88%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol Myers Squibb stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president directly owned 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds have recently added to or reduced their stakes in the stock. Polar Asset Management Partners Inc. bought a new position in Bristol Myers Squibb during the fourth quarter valued at about $16,651,000. Avaii Wealth Management LLC grew its stake in Bristol Myers Squibb by 590.9% during the first quarter. Avaii Wealth Management LLC now owns 78,597 shares of the biopharmaceutical company's stock valued at $4,794,000 after acquiring an additional 67,221 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Bristol Myers Squibb by 1.4% in the first quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company's stock worth $3,967,000 after buying an additional 869 shares in the last quarter. Shorepoint Capital Partners LLC increased its stake in Bristol Myers Squibb by 2.2% in the 4th quarter. Shorepoint Capital Partners LLC now owns 58,426 shares of the biopharmaceutical company's stock worth $3,305,000 after acquiring an additional 1,248 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of Bristol Myers Squibb by 17.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 550,613 shares of the biopharmaceutical company's stock valued at $33,582,000 after acquiring an additional 80,087 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.